Abstract
This article reviews randomized control trials (RCTs) published in 2006 of various medications evaluated for stroke patients. These trials were primarily efficacy studies. These included aggrenox (an antiplatelet agent), magnesium (to treat arterial spasm after an aneurysmal subarachnoid hemorrhage), NXY (a free radical trapping agent) and albumin which were both tested as a neuroprotectant, amphetamine (to aid motor recovery), fluoxetine (an anti-depressant and anxiolytic) and low molecular weight heparin (for prevention of deep vein thrombosis post-stroke).
Keywords: Randomized control trials, stroke, rehabilitation
Current Vascular Pharmacology
Title: Randomized Clinical Stroke Trials in 2006
Volume: 6 Issue: 1
Author(s): Meheroz H. Rabadi and John P. Blass
Affiliation:
Keywords: Randomized control trials, stroke, rehabilitation
Abstract: This article reviews randomized control trials (RCTs) published in 2006 of various medications evaluated for stroke patients. These trials were primarily efficacy studies. These included aggrenox (an antiplatelet agent), magnesium (to treat arterial spasm after an aneurysmal subarachnoid hemorrhage), NXY (a free radical trapping agent) and albumin which were both tested as a neuroprotectant, amphetamine (to aid motor recovery), fluoxetine (an anti-depressant and anxiolytic) and low molecular weight heparin (for prevention of deep vein thrombosis post-stroke).
Export Options
About this article
Cite this article as:
Rabadi H. Meheroz and Blass P. John, Randomized Clinical Stroke Trials in 2006, Current Vascular Pharmacology 2008; 6 (1) . https://dx.doi.org/10.2174/157016108783331259
DOI https://dx.doi.org/10.2174/157016108783331259 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Therapeutic Potential of microRNAs in Vascular Disease)
Current Vascular Pharmacology Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Antiplatelet Therapy and Oral Anticoagulation for Prevention of Ischemic Stroke
Current Drug Therapy Endogenous Events Modulating Myogenic Regulation of Cerebrovascular Function
Current Vascular Pharmacology Postconditioning: A New Paradigm for Myocardial Protection?
Current Cardiology Reviews Novel Inflammatory Biomarkers in Cardiovascular Therapeutics
Current Medicinal Chemistry Revision on Renal Sympathetic Ablation in the Treatment of Resistant Hypertension
Current Hypertension Reviews Spreading Depolarization Waves in Neurological Diseases: A Short Review about its Pathophysiology and Clinical Relevance
Current Neuropharmacology Urokinase-a Very Popular Cardiovascular Agent
Recent Patents on Cardiovascular Drug Discovery Red Wine Consumption and Prevention of Atherosclerosis: An In Vitro Model Using Human Peripheral Blood Mononuclear Cells
Current Pharmaceutical Design Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome
Drug Metabolism Letters Myocardial Infarction after Rituximab Treatment for Rheumatoid Arthritis: Is there a Link?
Current Pharmaceutical Design Levosimendan Preoperative
Current Pharmaceutical Design Cardiovascular Magnetic Resonance Imaging: State of the Art
Current Cardiology Reviews Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19
Current Medicinal Chemistry Behçets Disease as an Autoinflammatory Disorder
Current Drug Targets - Inflammation & Allergy Neuroimaging of Non-Accidental Injury
Current Pediatric Reviews Genetic Variation and Atherosclerosis
Current Genomics Anti-epileptic Drug (AED) Use in Subarachnoid Hemorrhage (SAH) and Intracranial Hemorrhage (ICH)
Current Pharmaceutical Design